Morgan Stanley Sticks to Their Buy Rating for Life360 Shs Chess Depository Interests Repr 3 Sh (LIFX)

Morgan Stanley analyst James Bales maintained a Buy rating on Life360 Shs Chess Depository Interests Repr 3 Sh (LIFX – Research Report) today and set a price target of A$40.00. The company's shares closed last Friday at $20.00.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Bales covers the Consumer Cyclical sector, focusing on stocks such as Corporate Travel Management Limited, Flight Centre Travel Group Limited, and WEB Travel Group. According to TipRanks, Bales has an average return of -1.0% and a 39.85% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Life360 Shs Chess Depository Interests Repr 3 Sh with a $19.63 average price target.
Based on Life360 Shs Chess Depository Interests Repr 3 Sh's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $115.53 million and a net profit of $8.5 million. In comparison, last year the company earned a revenue of $86.96 million and had a GAAP net loss of $3.15 million

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

an hour ago

• Business Insider

Dassault Systemes price target lowered to EUR 27 from EUR 28 at Jefferies

Jefferies lowered the firm's price target on Dassault Systemes (DASTY) to EUR 27 from EUR 28 and keeps an Underperform rating on the shares. The firm says ongoing macro uncertainty means positive surprises are unlikely in the company's Q2. It believes questions over whether Dassault will meet guidance are persist until year-end. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

2 hours ago

• Business Insider

Sarepta price target lowered to $30 from $84 at JPMorgan

JPMorgan lowered the firm's price target on Sarepta (SRPT) to $30 from $84 and keeps an Overweight rating on the shares. The firm made changes to its revenue assumptions for key Elevidys post the disclosure of second non-ambulatory patient death. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

2 hours ago

• Business Insider

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics (SAGE) to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>